The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 No. 832

Amendment to Schedule 8C

138.  In Schedule 8C (material to accompany an application under the unfettered access route)(1)—

(a) in paragraph 1, omit “EU marketing authorisation or”;

(b) in paragraph 2, omit “EU marketing authorisation or”;

(c) in paragraph 3, omit “EU marketing authorisation or”.

(1)

Schedule 8C was inserted by S.I. 2019/775 as amended by S.I. 2020/1488.